Septerna to present at J.P. Morgan Healthcare event

Septerna, Inc. filed a Form 8-K to notify investors that the company will be holding meetings with participants at the 44th Annual J.P.

Rhea-AI Filing Summary

Septerna, Inc. filed a Form 8-K to notify investors that the company will be holding meetings with participants at the 44th Annual J.P. Morgan Healthcare Conference during the week of January 12, 2026. The company prepared an investor presentation for these meetings, which is furnished as Exhibit 99.1 and incorporated by reference. This material is being provided as "furnished" information under Item 7.01, meaning it is not treated as filed for liability purposes or automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Septerna, Inc. (SEPN) disclose in this Form 8-K?

Septerna, Inc. disclosed that it will hold meetings with participants at the 44th Annual J.P. Morgan Healthcare Conference during the week of January 12, 2026, and that an accompanying presentation is furnished as Exhibit 99.1.

What is Exhibit 99.1 in Septerna, Inc.’s 8-K filing?

Exhibit 99.1 is the presentation Septerna, Inc. is using in meetings at the 44th Annual J.P. Morgan Healthcare Conference, and it is incorporated into the report by reference as furnished information.

Is the Septerna (SEPN) J.P. Morgan Healthcare Conference presentation considered filed with the SEC?

No. The company states that the information in Item 7.01 and Exhibit 99.1 is furnished, not filed, for purposes of Section 18 of the Exchange Act and is not subject to related liabilities, unless later specifically incorporated by reference.

Does this Septerna, Inc. Form 8-K include new financial results or earnings data?

No. The disclosure focuses on Septerna, Inc.’s participation in the 44th Annual J.P. Morgan Healthcare Conference and the furnishing of a related presentation, without providing financial or earnings figures.

Who signed this Septerna, Inc. Form 8-K?

The Form 8-K was signed on behalf of Septerna, Inc. by Jeffrey Finer, M.D., Ph.D., who is identified as the company’s Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/12/2026 - 08:30 AM EST Learn about SEC filing dates

false 0001984086 0001984086 2026-01-12 2026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

Septerna, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-42382		84-3891440
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
250 East Grand Avenue
South San Francisco, California				94080
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 650 338-3533

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		SEPN		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

Septerna, Inc. will be conducting meetings with participants attending the 44th Annual J.P. Morgan Healthcare Conference during the week of January 12, 2026. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference.

The information in Item 7.01 of this Current Report on Form 8-K, including the accompanying Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Corporate Presentation of Septerna, Inc., dated January 2026, furnished herewith.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						Septerna, Inc.
Date: January 12, 2026				By:		/s/ Jeffrey Finer, M.D., Ph.D.
						Jeffrey Finer, M.D., Ph.D. Chief Executive Officer